Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma

Article Type

Article

Changed

Fri, 01/04/2019 - 11:12

Display Headline

Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

In the fall of 2015, the United States joined the growing list of countries in which trabectedin, a novel form of chemotherapy, is approved for the treatment of certain types of advanced soft tissue sarcoma. The drug, a synthetic derivative of a compound originally isolated from a sea squirt, has a complex mechanism of action that distinguishes it from other cytotoxic drugs, allowing it to target both the tumor and its microenvironment. Based on the results of a randomized, open-label, multicenter phase 3 clinical trial, trabectedin received regulatory approval for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_May_189_Abraham.pdf

Issue

The Journal of Community and Supportive Oncology - 14(5)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Sarcoma & GIST

Page Number

189-191

Legacy Keywords

trabectedin, soft tissue sarcoma, ET743-SAR-3007, liposarcoma, leiomyosarcoma, dacarbazine

Sections

Community Translations

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Article PDF

JCSO_May_189_Abraham.pdf

Article PDF

JCSO_May_189_Abraham.pdf

In the fall of 2015, the United States joined the growing list of countries in which trabectedin, a novel form of chemotherapy, is approved for the treatment of certain types of advanced soft tissue sarcoma. The drug, a synthetic derivative of a compound originally isolated from a sea squirt, has a complex mechanism of action that distinguishes it from other cytotoxic drugs, allowing it to target both the tumor and its microenvironment. Based on the results of a randomized, open-label, multicenter phase 3 clinical trial, trabectedin received regulatory approval for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma.

Click on the PDF icon at the top of this introduction to read the full article.

In the fall of 2015, the United States joined the growing list of countries in which trabectedin, a novel form of chemotherapy, is approved for the treatment of certain types of advanced soft tissue sarcoma. The drug, a synthetic derivative of a compound originally isolated from a sea squirt, has a complex mechanism of action that distinguishes it from other cytotoxic drugs, allowing it to target both the tumor and its microenvironment. Based on the results of a randomized, open-label, multicenter phase 3 clinical trial, trabectedin received regulatory approval for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 14(5)

Issue

The Journal of Community and Supportive Oncology - 14(5)

Page Number

189-191

Page Number

189-191

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology